Skip to main navigation Skip to search Skip to main content

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): A phase 3 randomised trial

  • Jean Charles Soria
  • , Yi Long Wu
  • , Kazuhiko Nakagawa
  • , Sang We Kim
  • , Jin Ji Yang
  • , Myung Ju Ahn
  • , Jie Wang
  • , James Chih Hsin Yang
  • , You Lu
  • , Shinji Atagi
  • , Santiago Ponce
  • , Dae Ho Lee
  • , Yunpeng Liu
  • , Kiyotaka Yoh
  • , Jian Ying Zhou
  • , Xiaojin Shi
  • , Alan Webster
  • , Haiyi Jiang
  • , Tony S.K. Mok
  • Gustave Roussy
  • Guangdong Academy of Medical Sciences
  • Kindai University
  • University of Ulsan
  • Sungkyunkwan University
  • Peking University
  • National Taiwan University
  • Sichuan University
  • National Hospital Organization Kinki-Chuo Chest Medical Center
  • Hospital Universitario 12 de Octubre
  • The First Hospital of China Medical University
  • National Cancer Center Japan
  • Zhejiang University
  • AstraZeneca
  • Prince of Wales Hospital Hong Kong

Research output: Contribution to journal › Article › peer-review

404   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): A phase 3 randomised trial'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry